Nov 10 (Reuters) – Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to invest billions into building U.S. sites.<\/p>\n
The plant will produce radioligand therapies, which are drugs that deliver cell-killing radioactive particles directly to tumors, the company said. Novartis already markets radioligand drugs Pluvicto for prostate cancer and Lutathera for rare gastrointestinal tumors.<\/p>\n
Sign up here.<\/a><\/p>\n The new factory will speed up and stabilize delivery of radioligand therapy doses to patients across the western U.S., Alaska, and Hawaii, Novartis said.<\/p>\n Novartis in April pledged $23 billion to build and expand 10 facilities in the U.S., as it grappled with renewed threats of drug import duties from the Trump administration.<\/p>\n The company said it planned to build six new manufacturing plants, some of which will make raw pharmaceutical ingredients, as well as a new research and development site in San Diego, California.<\/p>\n Reporting by Patrick Wingrove in New York; Editing by Bill Berkrot<\/p>\n Our Standards: The Thomson Reuters Trust Principles., opens new tab<\/a><\/p>\n